|
References: N, O, P
- Naylor, G. T., J. M. Donald, D. Le Poidevin, and A. H. Reid. 1974. A double-blind trial of long-term lithium therapy in mental defectives. Br. J. Psychiatry 124:52-57.
- O'Hare, J. P., I. A. D. O'Brian, J. Arendt, P. Astley, W. Ratcliffe, H. Andres, R. Walters, and R. S. M. Correll. 1986. Does melatonin deficiency cause the enlarged genitalia of the fragile X syndrome?
Clin. Endocrinol. 24:327-333.
- Olvera, R. L., S. R. Pliszka, J. Luh, and R. Tatum. 1996. An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J. Child Adolesc.
Psychopharmacol. 6:241-250.
- Pascualvaca, D. 1995. Attention capacities in children with pervasive developmental disorders. Int. Pediatr. 10:166-170.
- Pelco, L. E., R. C. Kissel, J. M. Parrish, and R. G. Miltenberger. 1987. Behavioral management of oral medication administration difficulties among children: A review of literature with case
illustrations. J. Dev. Behav. Pediatr. 8:90-96.
- Pelham, W. E., H. R. Aronoff, J. K. Midlam, C. J. Shapiro, E. M. Gnagy, A. M. Chronis, A. N. Onyango, G. Forehand, A. Nguyen, and J. Waxmonsky. 1999. A comparison of ritalin and Adderall: Efficacy and
time-course in children with attention-deficit/hyperactivity disorder. Pediatrics 103:e43.
- Pellock, J. M. 1987. Carbamazepine side effects in children and adults. Epilepsia 28 (suppl. 3): S64-S70.
- Pippenger, C. E. 1987. Clinically significant carbamazepine drug interactions: An overview. Epilepsia 28 (suppl. 3): S71-S76.
- Pliszka, S. R. 1987. Tricyclic antidepressants in the treatment of children with attention deficit disorder. J. Am. Acad. Child Adolesc. Psychiatry 26:127-132.
- Pliszka, S. R., J. T. McCracken, and J. W. Maas. 1996. Catecholamines in attention deficit hyperactivity disorder: Current perspectives. J. Am. Acad. Child Adolesc. Psychiatry 35:264-272.
- Polakoff, S. A., P. J. Sorgi, and J. J. Ratey. 1986. The treatment of impulsive and aggressive behavior with nadolol. J. Clin. Psychopharmacol. 6:125-126.
- Post, R. M. 1989. Introduction: Emerging perspectives on valproate in affective disorders. J. Clin. Psychiatry 50 (suppl. 3): 3-9.
- Post, R. M., M. A. Frye, and G. S. Leverich. 1998. The role of complex combination therapy in the treatment of refractory bipolar illness. CNS Spectrums 3:66-86.
- Potenza, M. N., J. P. Holmes, S. J. Kanes, and C. J. McDougle. 1999. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study. J.
Clin. Psychopharmacol. 19:37-44.
- Preskorn, S. H. 1993. Recent pharmacologic advances in antidepressant therapy for the elderly. Am. J. Med. 94 (suppl. 5A): 2S-12S.
- ---. 1994. Antidepressant drug selection: Criteria and options. J. Clin. Psychiatry 55 (suppl. 9): 6-22.
- Prince, J. B., T. E. Wilens, J. Biederman, T. J. Spencer, and J. R. Wozniak. 1996. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: A systematic chart review
of 62 cases. J. Am. Acad. Child Adolesc. Psychiatry 35:599-605.
|
This article is not intended to give medical advice for individual cases. Any change in medical treatment
should be done in consultation with appropriate medical personnel. This article is written for medical professionals. Some of the terms will be unfamiliar to those who are not trained in medical fields.
*This article is from the chapter on treatment in the 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research edited
by Randi Jenssen Hagerman, M.D. and Paul Hagerman, M.D., Ph.D., to be published May 2002. It is included with permission from The Johns Hopkins University Press. References to other chapters refer to chapters in
the book which are not included as part of this website.
The complete 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research can be ordered from the National Fragile X Foundation by calling
1-800-688-8765 or from The Johns Hopkins University Press at 1-800-537-5487.
|
|
Medical Follow-up Pharmacotherapy Future Prospects
Outline Medications Medical Conditions
References: A, B, C, D, EF, G, H, IJ, K, L, M, NOP, QR, S, T, UVWXYZ
|
|
